* positive sars-cov-2 antigenic test * positive sars-cov-2 polymerase chain reaction (pcr) results less than 48 hours old * history of infection by sars-cov-2 confirmed by antigenic test or pcr within 3 months prior to inclusion * symptoms compatible with infection to sars-cov-2: sick or febrile participants (body temperature ≥ 38.0°c) * pregnant or breastfeeding woman * known chronic disease impacting the participant's immune response (uncured cancer, human immunodeficiency virus (hiv), hepatitis b virus (hbv) or hepatitis c virus (hcv) infection) * anti-coagulant treatment * immunosuppressive treatment * contraindication to the proposed vaccine (according to rcp) * previously received at least one injection of a sars-cov-2 vaccine * patient having received immunoglobulin or another blood product within 3 months prior to inclusion * a history of serious adverse vaccine reactions (anaphylaxis and associated symptoms such as rash, breathing difficulties, laryngeal edema, or a history of allergic reaction that may be exacerbated by a component of the sars-cov-2 vaccine) * any condition that, in the opinion of the investigator, may adversely affect the well-being of the participant and interfere with the purpose of the study

* positive sars-cov-2 antigenic test * positive sars-cov-2 polymerase chain reaction (pcr) results less than 48 hours old * history of infection by sars-cov-2 confirmed by antigenic test or pcr within 3 months prior to inclusion * symptoms compatible with infection to sars-cov-2: sick or febrile participants (body temperature ≥ 38.0°c) * pregnant or breastfeeding woman * known chronic disease impacting the participant's immune response (uncured cancer, human immunodeficiency virus (hiv), hepatitis b virus (hbv) or hepatitis c virus (hcv) infection) * anti-coagulant treatment * immunosuppressive treatment * contraindication to the proposed vaccine (according to rcp) * previously received at least one injection of a sars-cov-2 vaccine * patient having received immunoglobulin or another blood product within 3 months prior to inclusion * a history of serious adverse vaccine reactions (anaphylaxis and associated symptoms such as rash, breathing difficulties, laryngeal edema, or a history of allergic reaction that may be exacerbated by a component of the sars-cov-2 vaccine) * any condition that, in the opinion of the investigator, may adversely affect the well-being of the participant and interfere with the purpose of the study

positive sars-cov-2 antigenic test positive sars-cov-2 polymerase chain reaction (pcr) results less than 48 hours old history of infection by sars-cov-2 confirmed by antigenic test or pcr within 3 months prior to inclusion symptoms compatible with infection to sars-cov-2: sick or febrile participants (body temperature ≥ 38.0°c) pregnant or breastfeeding woman known chronic disease impacting the participant's immune response (uncured cancer, human immunodeficiency virus (hiv), hepatitis b virus (hbv) or hepatitis c virus (hcv) infection) anti-coagulant treatment immunosuppressive treatment contraindication to the proposed vaccine (according to rcp) previously received at least one injection of a sars-cov-2 vaccine patient having received immunoglobulin or another blood product within 3 months prior to inclusion a history of serious adverse vaccine reactions (anaphylaxis and associated symptoms such as rash, breathing difficulties, laryngeal edema, or a history of allergic reaction that may be exacerbated by a component of the sars-cov-2 vaccine) any condition that, in the opinion of the investigator, may adversely affect the well-being of the participant and interfere with the purpose of the study

positive sars-cov-2 antigenic test positive sars-cov-2 polymerase chain reaction (pcr) results less than 48 hours old history of infection by sars-cov-2 confirmed by antigenic test or pcr within 3 months prior to inclusion symptoms compatible with infection to sars-cov-2: sick or febrile participants (body temperature ≥ 38.0°c) pregnant or breastfeeding woman known chronic disease impacting the participant's immune response (uncured cancer, human immunodeficiency virus (hiv), hepatitis b virus (hbv) or hepatitis c virus (hcv) infection) anti-coagulant treatment immunosuppressive treatment contraindication to the proposed vaccine (according to rcp) previously received at least one injection of a sars-cov-2 vaccine patient having received immunoglobulin or another blood product within 3 months prior to inclusion a history of serious adverse vaccine reactions (anaphylaxis and associated symptoms such as rash, breathing difficulties, laryngeal edema, or a history of allergic reaction that may be exacerbated by a component of the sars-cov-2 vaccine) any condition that, in the opinion of the investigator, may adversely affect the well-being of the participant and interfere with the purpose of the study

None

None